-$0.10 EPS Expected for Anavex Life Sciences Corp. (AVXL) This Quarter
Equities research analysts forecast that Anavex Life Sciences Corp. (NASDAQ:AVXL) will post ($0.10) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Anavex Life Sciences’ earnings. Anavex Life Sciences posted earnings per share of ($0.18) in the same quarter last year, which would suggest a positive year over year growth rate of 44.4%. The company is expected to announce its next quarterly earnings report on Monday, December 11th.
According to Zacks, analysts expect that Anavex Life Sciences will report full-year earnings of ($0.36) per share for the current year. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Anavex Life Sciences.
A number of equities analysts have recently commented on the stock. Zacks Investment Research raised shares of Anavex Life Sciences from a “hold” rating to a “buy” rating and set a $5.50 target price on the stock in a research report on Wednesday, September 6th. Maxim Group set a $15.00 price objective on shares of Anavex Life Sciences and gave the stock a “buy” rating in a research note on Monday, October 30th. ValuEngine cut shares of Anavex Life Sciences from a “hold” rating to a “sell” rating in a report on Thursday, September 28th. Finally, Noble Financial reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Anavex Life Sciences in a report on Friday, September 29th.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Wells Fargo & Company MN grew its position in shares of Anavex Life Sciences by 40.8% in the third quarter. Wells Fargo & Company MN now owns 56,873 shares of the biotechnology company’s stock valued at $236,000 after purchasing an additional 16,488 shares during the period. SNS Financial Group LLC acquired a new position in Anavex Life Sciences during the third quarter worth about $290,000. The Manufacturers Life Insurance Company boosted its position in Anavex Life Sciences by 37.7% during the second quarter. The Manufacturers Life Insurance Company now owns 31,876 shares of the biotechnology company’s stock worth $169,000 after acquiring an additional 8,728 shares during the last quarter. State Street Corp boosted its position in Anavex Life Sciences by 15.2% during the second quarter. State Street Corp now owns 603,326 shares of the biotechnology company’s stock worth $3,210,000 after acquiring an additional 79,516 shares during the last quarter. Finally, Virtu KCG Holdings LLC acquired a new position in Anavex Life Sciences during the second quarter worth about $186,000. Institutional investors and hedge funds own 23.88% of the company’s stock.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related stocks with our FREE daily email newsletter.